Antibody therapeutics - the evolving patent landscape

New Biotechnology

Volumn 28, Issue 5, 2011, Pages 538-544

  Petering, Jenny ^a   McManamny, Patrick ^a   Honeyman, Jane ^a  

^a FB Rice   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PATENTS AND INVENTIONS;

ANTIBODY THERAPEUTICS; IMMUNOGENICITY; PATENT PROTECTION;

ANTIBODIES;

ADALIMUMAB; ANTIBODY; BEVACIZUMAB; CETUXIMAB; CHIMERIC ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; PALIVIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB;

ANTIBODY PRODUCTION; CANADA; COLOMBIA; CYTOMEGALOVIRUS; GENOME; HUMAN; IMMUNOGENICITY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTECTION; PROTEIN MODIFICATION; REVIEW; UNITED STATES;

EID: 80052815687     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.03.023     Document Type: Review

References (3)

1. Mehdiratta R., Saberwal Bio-business in brief: many a monoclonal. Curr. Sci. 2007, 93:789-796.
2. Waltz M. Genentech's Cabilly Victory. Nat. Biotechnol. 2009, 27:307.
3. Novartis sues over monoclonal antibodies. Nat. Rev.: Drug Discov. 2011, 10:168.